Neil Almstead

2016

In 2016, Neil Almstead earned a total compensation of $1.6M as Executive Vice President, Research, Pharmaceutical Operations & Technology at PTC Therapeutics, a 42% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$143,582
Option Awards$1,054,400
Salary$422,300
Other$8,566
Total$1,628,847

Almstead received $1.1M in option awards, accounting for 65% of the total pay in 2016.

Almstead also received $143.6K in non-equity incentive plan, $422.3K in salary and $8.6K in other compensation.

Rankings

In 2016, Neil Almstead's compensation ranked 5,866th out of 14,075 executives tracked by ExecPay. In other words, Almstead earned more than 58.3% of executives.

ClassificationRankingPercentile
All
5,866
out of 14,075
58th
Division
Manufacturing
2,125
out of 5,489
61st
Major group
Chemicals And Allied Products
696
out of 1,895
63rd
Industry group
Drugs
525
out of 1,538
66th
Industry
Pharmaceutical Preparations
416
out of 1,176
65th
Source: SEC filing on April 27, 2017.

Almstead's colleagues

We found four more compensation records of executives who worked with Neil Almstead at PTC Therapeutics in 2016.

2016

Stuart Peltz

PTC Therapeutics

Chief Executive Officer

2016

Shane Kovacs

PTC Therapeutics

Chief Financial Officer

2016

Mark Rothera

PTC Therapeutics

Chief Commercial Officer

2016

Mark Boulding

PTC Therapeutics

Chief Legal Officer

News

In-depth

You may also like